In a patient with NSTEMI who took 5 mg apixaban (Eliquis) this morning, should I start an unfractionated heparin infusion?

Do Not Start Heparin Drip Without Considering Apixaban Timing and Bleeding Risk

You should NOT routinely start a heparin infusion in a patient with NSTEMI who took apixaban (Eliquis) 5 mg yesterday morning without first assessing the timing, bleeding risk, and planned management strategy. The decision requires careful consideration of apixaban's pharmacokinetics, your invasive strategy timing, and the risk-benefit profile of adding parenteral anticoagulation on top of residual DOAC activity.

Key Clinical Considerations

Apixaban Pharmacokinetics and Residual Effect

Apixaban has a half-life of approximately 12 hours, meaning that 24 hours after the last dose (yesterday morning), the patient still has approximately 25% of peak drug levels remaining 1. The FDA label explicitly states that "the pharmacodynamic effect of ELIQUIS can be expected to persist for at least 24 hours after the last dose" 1. This residual anticoagulant effect creates a significant bleeding risk if you layer on full-dose heparin without consideration.

Guideline-Based Approach to Anticoagulation in NSTEMI

The most recent 2025 ACC/AHA guidelines provide clear direction: parenteral anticoagulation (UFH, enoxaparin, fondaparinux, or bivalirudin) is recommended for all NSTEMI patients to reduce ischemic events 2. However, these guidelines were developed for patients NOT already on therapeutic anticoagulation with DOACs.

For standard NSTEMI management:

• UFH is useful to reduce ischemic events (Class I, Level B-R) 2
• Anticoagulation should be continued until revascularization 2
• The 2020 ESC guidelines similarly recommend parenteral anticoagulation for all patients at the time of diagnosis 3

The Critical Problem: DOAC Interference

The major issue is that apixaban interferes with heparin monitoring assays, making therapeutic management extremely challenging 4, 5:

• Heparin anti-Xa assays are affected by DOACs and show falsely elevated levels 4
• aPTT is also unreliable in the presence of residual DOAC activity 4
• This leads to delayed heparin initiation and difficulty achieving therapeutic anticoagulation 4

A 2023 study specifically examining NSTEMI patients on DOACs found that elevated baseline anti-Xa levels (from apixaban) resulted in delayed heparin therapy, though notably there was no increase in mortality 4.

Recommended Management Algorithm

Step 1: Determine Your Invasive Strategy Timing

If Early Invasive Strategy (PCI within 24-72 hours):

• Wait for apixaban to clear before starting heparin if PCI is planned within the next 12-24 hours
• The residual apixaban will provide some anticoagulation during this brief period
• Start UFH at the time of PCI using standard weight-based dosing (70-100 U/kg bolus targeting ACT 250-300 seconds) 2, 3
• This avoids the monitoring difficulties and excessive bleeding risk of overlapping anticoagulants

If Delayed Invasive or Conservative Strategy:

• Consider starting heparin infusion after 36-48 hours from the last apixaban dose when drug levels are minimal
• If you must start earlier due to high ischemic risk, use reduced initial dosing and monitor closely for bleeding
• Baseline anti-Xa level may help identify residual DOAC activity 5

Step 2: If You Must Start Heparin with Residual Apixaban

When clinical urgency demands immediate anticoagulation despite recent apixaban:

1. Use conservative initial dosing: Consider 50-60 U/kg bolus (rather than standard 70-100 U/kg) followed by 12 U/kg/hr infusion 2
2. Obtain baseline heparin anti-Xa level to document residual DOAC activity 5
3. Delay first monitoring level until 6 hours after initiation, as most down-titrations occur in the first 6 hours 5
4. Expect monitoring challenges: Most up-titrations occur after 36 hours when DOAC has cleared 5
5. Monitor closely for bleeding complications

Step 3: Alternative Anticoagulation Strategies

Consider enoxaparin instead of UFH if conservative management is planned:

• Enoxaparin is preferred over UFH for conservative strategy (Class IIa, Level B) 6
• Dosing: 1 mg/kg subcutaneous every 12 hours 2
• Less monitoring required, avoiding the DOAC interference problem
• Associated with lower ischemic complications and better safety profile in NSTEMI 7

Fondaparinux is another alternative:

• Recommended for conservative strategy (Class IIa, Level B) 6
• Critical caveat: If patient proceeds to PCI, you MUST add UFH bolus to prevent catheter thrombosis 3

Common Pitfalls to Avoid

1. Do not assume you can monitor heparin normally: The anti-Xa assay will be falsely elevated for at least 24-36 hours after the last apixaban dose 4, 5

2. Do not use full-dose heparin immediately: This creates excessive bleeding risk with residual DOAC activity 1

3. Do not bridge with heparin if PCI is imminent: The FDA label explicitly states "bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required" 1

4. Do not forget that apixaban provides SOME anticoagulation: Even at 24 hours post-dose, there is residual anticoagulant effect 1

Bottom Line

For a patient with NSTEMI who took 5 mg apixaban yesterday morning, the optimal approach is to proceed directly to early PCI (within 24-48 hours) and start UFH at the time of catheterization, rather than starting a heparin drip now. If early PCI is not feasible and you need anticoagulation for a conservative strategy, wait 36-48 hours from the last apixaban dose before starting heparin, or use enoxaparin/fondaparinux as alternatives that require less monitoring. Starting a heparin drip immediately creates significant monitoring challenges, increases bleeding risk, and provides minimal additional benefit given the residual apixaban activity.